Visionary (GV) – Press Releases
-
Visionary Selects YCM CPA INC as its Independent Registered Public Accounting Firm
-
Visionary Announces Board Changes
-
Visionary Announces Name Change
-
Visionary Education Group Established a MOU with Algoma University
-
DELETED: Visionary Education Group Established a MOU with Algoma University
-
Visionary Education Group Established a MOU with Algoma University
-
GV Announces Successfully Held Global Chinese Capital Establishment Conference
-
Visionary Education Technology Holdings Group Inc. Announces Results of 2023 Annual General Meeting and Receipt of NASDAQ Extension Letter
-
Algoma University Executives Visited GV Headquarter in Toronto
-
Genomic Vision Announces the Opening of a Receivership Proceedings
-
Genomic Vision: Financial Information for the Third Quarter of 2023
-
GV Announces Terminated Mr. Charlie Penn's employment as COO
-
GV to Hold Annual Shareholder Meeting on December 11, 2023
-
Genomic Vision Requests Receivership Proceedings
-
Genomic Vision Expands Its Replication Combing Assay Service Offering
-
Genomic Vision at the 30th Annual European Society of Gene and Cell Therapy (ESGCT) Congress in Brussels from 25 to 26 October 2023
-
GV Announces A New Sharing Education Program
-
GV is Entering a Memorandum with A College for International Education
-
Genomic Vision Reduces Replication Combing Assay Turnaround Time for Pharmaceutical Industry and Advances Drug Discovery and Oncology
-
GV Launches Winter Session for International Students
-
Genomic Vision: First-Half 2023 Results
-
Genomic Vision Attended the 20th Edition of the European Drug Discovery Innovation Programme in Barcelona
-
Genomic Vision Launches HexaCard, a New Service for Characterizing Transformed Cell Lines
-
Genomic Vision Announces the Issuance of the 3rd Tranche of Convertible Notes With Warrants (OCABSA) for €2 Million, as Part of the Financing Line Concluded With Winance for a Maximum Amount of €3
-
Genomic Vision Enters Distribution Agreement with CliniSciences
-
Genomic Vision Enters Technology Agreement With The Institute of Cancer Research, London
-
Genomic Vision Provides Strategy Update
-
Genomic Vision: Financial Information for the First Quarter of 2023
-
Genomic Vision: 2022 Annual Results
-
Genomic Vision Joins France BioLead to Advance Innovation and Production of Biopharmaceuticals in France
-
Genomic Vision launches FiberSmart®, AI-powered software for automating genomic analysis
-
Genomic Vision: Financial Information for the Fourth Quarter of 2022
-
The US National Institute of Standards and Technology (NIST) has evaluated the use of Genomic Vision applications for genetic variant characterization
-
The US National Institute of Standards and Technology (NIST) has evaluated the use of Genomic Vision applications for genetic variant characterization
-
Genomic Vision announces the issuance of the 2nd tranche of convertible notes with warrants (OCABSA) for €2 million, as part of the financing line concluded with Winance for a maximum amount of €3
-
Genomic Vision Strengthens Leadership Team With the Appointment of Frederic Hammel as Chief Operating Officer
-
Genomic Vision Announces Successful Beta Testing of FiberSmart®
-
Genomic Vision’s Cutting-Edge TeloSizer® Application to be Used in Cancer Research
-
Genomic Vision and Cambridge Consultants, Part of Capgemini, Announce the Development of an Innovative Technology Platform for In-depth Genomic Analysis
-
Genomic Vision: Financial Information for the Third Quarter of 2022
-
Genomic Vision: Press Release Regarding Changes in the Company’s Governance
-
Genomic Vision: First-half 2022 Results
-
Genomic Vision Announces the Issuance of the 1st Tranche of Convertible Notes With Warrants (OCABSA) for €2 Million, as Part of the Financing Line Concluded With Winance for a Maximum Amount of €3
-
Genomic Vision: Financial Information for the First Half of 2022
-
Genomic Vision: Additional Contribution to the Liquidity Contract Concluded with CM-CIC Securities
-
Genomic Vision: Changes in the Company’s Governance
-
Genomic Vision Obtains the Renewal of the ISO 13485 : 2016 Certification
-
Genomic Vision granted a new patent for its “Physical Characterization of Telomeres” technique based on molecular combing
-
Genomic Vision Announces the Approval by Its Shareholders’ Meeting of All the Resolutions Supported by the Executive Board
-
Genomic Vision Announces the Signing of an Addendum to the Contract Signed with Winance on April 11, 2022 for the Purpose of Implementing a New Financing Line, Subject to the Prior Approval of the Com
Back to GV Stock Lookup